JP Morgan Maintains Overweight on iRhythm Technologies, Raises Price Target to $190
JP Morgan analyst Allen Gong maintains iRhythm Technologies (NASDAQ:IRTC) with a Overweight and raises the price target from $185 to $190.
Chemours, Alcoa And Other Big Losers From Wednesday
U.S. stocks closed lower with the Dow Jones dropping more than 500 points on Tuesday. Here is the list of some big stocks recording losses in the previous session.
Canaccord Genuity Maintains Buy on iRhythm Technologies, Raises Price Target to $198
Canaccord Genuity analyst William Plovanic maintains iRhythm Technologies (NASDAQ:IRTC) with a Buy and raises the price target from $185 to $198.
iRhythm Reports Smaller Than Expected Q2 Loss; Narrows Annual Sales Guidance
iRhythm Technologies Inc (NASDAQ:IRTC) posted a Q2 adjusted loss of $(0.79) compared to a loss of $(0.59) a year ago, beating…
Earnings Scheduled For August 4, 2022
Companies Reporting Before The Bell
• Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.
Recap Of Friday’s Biotech Catalysts – End Of The Day Summary
Bristol Myers Squibb (NYSE:BMY) received European Medicines Agency (EMA) Positive CHMP Opinion recommending approval for Opdualag (nivolumab and…
FDA Clears iRhythm’s ZEUS System For Zio Watch Made In Partnership With Google’s Verily
iRhythm Technologies Inc (NASDAQ:IRTC) has received FDA 510(k) clearance for its ZEUS (Zio ECG Utilization Software) System for the Zio Watch. …
iRhythm Gains FDA Clearance For Its Clinically Integrated ZEUS System
iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced it received FDA 510(k) clearance for its ZEUS (Zio ECG Utilization